BioNTech buys China's Biotheus to support oncology strategy
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on Wednesday.
BioNTech buys Biotheus and its Keytruda rival for $950m
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid tumours." It is paying $800 million to acquire all of Biotheus' issued share capital and up to $150 million in potential milestone payments.
BioNTech to buy Chinese biotech firm to boost oncology strategy
German drugmaker to use state-of-art antibody in tandem with advanced therapies to more effectively fight cancer, detect tumor cells in patients - Anadolu Ajansı
BioNTech Acquires Biotheus to Enhance Cancer Therapies
BioNTech SE (BNTX) has released an update. BioNTech SE is set to acquire Biotheus in a deal valued at $800 million, aiming to strengthen its
BioNTech to Acquire Biotheus in $950 Million Deal
BioNTech has agreed to acquire biotechnology company Biotheus for $800 million up front and up to $150 million in milestone payments. The German developer of RNA vaccines and immunotherapies said Wednesday that the acquisition builds on its oncology ...
Biontech übernimmt Biotechfirma Biotheus in China
Biontech verstärkt sich in der Entwicklung von Krebsmedikamenten durch einen Zukauf in China. Fast eine Milliarde Dollar lässt sich CEO Uğur Şahin die Übernahme kosten – er will damit in der Onkologie
BioNTech to acquire Biotheus for upfront consideration of $800M
BioNTech (BNTX) and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology
BioNTech to Acquire Biotheus to Boost Oncology Strategy
BioNTech SE (Nasdaq: BNTX, "BioNTech") and Biotheus ("Biotheus") today announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases.
BioNTech strikes $950mn deal for Chinese drugmaker Biotheus
BioNTech has acquired Chinese cancer drugmaker Biotheus in a near $1bn deal, as the Covid-19 vaccine maker taps into the country’s health sciences expertise to develop promising immunotherapy drugs. The deal gives the German biotech control of a drug class that has shown potential to outperform Merck’s blockbuster cancer treatment Keytruda,
FierceBiotech17h
BioNTech pays $800M to take control of potential Keytruda killer
BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus ...
STAT9h
BioNTech acquires its Chinese cancer drug partner
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
MM&M2h
BioNTech spends $800M upfront to pick up China-based Biotheus
BioNTech is shelling out $800 million upfront to acquire China-based Biotheus in a move that would give it access to a late ...
AOL9h
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
DPA International on MSN9h
Germany's BioNTech to buy Chinese firm with promising cancer drug
Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its ...
What Analysts Are Saying About BioNTech Stock
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...
BioNTech SE (BNTX) Gets a Buy from Morgan Stanley
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...